David Jin, MD, Ph.D. is the President, Chief Executive Officer and Co-founder of Avalon GloboCare Corp. (NASDAQ: AVCO), a clinical-stage biotech company dedicated to develop and deliver innovative and transformative cellular technologies and therapeutics in the fields of immuno-oncology and regenerative medicine. Dr. Jin also serves as co-CEO at SenlangBio, a wholly owned subsidiary of Avalon GloboCare. Prior to his current appointment, Dr. Jin served as Chief Medical Officer of BioTime Inc. and OncoCyte Corporation from 2009 to 2016.
Dr. Jin was previously appointed as scientific and clinical advisors for various domestic and international hospitals and biopharmaceutical companies for their hematology, oncology, immunotherapy and stem cell-based R&D program development. Dr. Jin has been Principal Investigator in more than 15 pre-clinical and clinical trials, as well as author/co-author of over 80 peer-reviewed scientific articles, abstracts, reviews, and book chapters. Dr. Jin received his combined M.D.-Ph.D. degree from SUNY Downstate College of Medicine in Brooklyn, NY. He received his clinical training and subsequent faculty tenure at the New York-Presbyterian Hospital (the teaching hospital for both Weill Cornell and Columbia Universities) in the areas of internal medicine, hematology and clinical oncology. At Weill Cornell, Dr. Jin served as a senior translational clinician-scientist at the Howard Hughes Medical Institute and the Ansary Stem Cell Institute. Dr. Jin was honored as Top Chief Medical Officer by ExecRank in 2012, as well as recognized as Leading Physicians of the World in 2015 and 2018